TY - JOUR
T1 - Treatment of extensively drug-resistant Gram-negative infections in critically ill patients
T2 - Outcome of a consensus meeting at the 13th Asia-Pacific Congress of Clinical Microbiology and Infection, October 2012
AU - Tambyah, Paul Anantharajah
AU - Hara, Gabriel Levy
AU - Daikos, George L.
AU - Falagas, Matthew E.
AU - Mazzei, Teresita
AU - Mouton, Johan W.
AU - Novelli, Andrea
AU - Chen, Baiyi
AU - Wang, Minggui
AU - Ko, Wen Chien
AU - Li, Taisheng
AU - Fan, Xinjian
AU - Theuretzbacher, Ursula
N1 - Funding Information:
Multicentre randomised studies, one funded by the 7th Framework Program of the European Union (EU) (AIDA-Preserving Old Antibiotics for the Future) and one clinical study funded by the US National Institute of Allergy and Infectious Diseases (NIAID), are underway to compare colistin treatment with a combination regimen of colistin + carbapenem. Until more information is available, CMS should be exclusively given to patients with infections caused by XDR Gram-negative bacteria susceptible only to colistin. This drug should not be used to treat infections caused by bacteria susceptible to other antibiotics and should not be used as a single drug although clinical evidence is currently scarce [22] .
PY - 2013
Y1 - 2013
N2 - Infections caused by multidrug-resistant and extensively drug-resistant Gram-negative bacilli are increasingly challenging to manage in hospitals and long term-care facilities worldwide. As the therapeutic options are limited, the International Society of Chemotherapy in collaboration with the Asia-Pacific Society of Clinical Microbiology and Immunology organised a consensus conference as part of the 13th Asia-Pacific Congress of Clinical Microbiology and Infection. A panel of international experts from Europe, the Americas and Asia were convened to discuss the issues of therapeutic options for the management of these difficult-to-treat pathogens.
AB - Infections caused by multidrug-resistant and extensively drug-resistant Gram-negative bacilli are increasingly challenging to manage in hospitals and long term-care facilities worldwide. As the therapeutic options are limited, the International Society of Chemotherapy in collaboration with the Asia-Pacific Society of Clinical Microbiology and Immunology organised a consensus conference as part of the 13th Asia-Pacific Congress of Clinical Microbiology and Infection. A panel of international experts from Europe, the Americas and Asia were convened to discuss the issues of therapeutic options for the management of these difficult-to-treat pathogens.
UR - http://www.scopus.com/inward/record.url?scp=84882343846&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84882343846&partnerID=8YFLogxK
U2 - 10.1016/j.jgar.2013.04.002
DO - 10.1016/j.jgar.2013.04.002
M3 - Review article
AN - SCOPUS:84882343846
SN - 2213-7165
VL - 1
SP - 117
EP - 122
JO - Journal of Global Antimicrobial Resistance
JF - Journal of Global Antimicrobial Resistance
IS - 3
ER -